The majority of experimental work has shown a positive correlation between leptin and pro-atherogenic effects, whereas an adverse cardiovascular profile in CKD patients in the clinical setting has been attributed to lower levels of leptin. The gene discussed is LEP; the disease is chronic kidney disease.